Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.20.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Operating activities    
Net loss $ (21,117,106) $ (7,454,048)
Adjustments to reconcile net loss used in operating activities:    
Depreciation and amortization 453,016 1,098,478
Stock-based compensation 1,116,323 596,693
Acquired in-process research and development, including transaction costs 25,549,344 0
Deferred taxes 20,720 5,941
Amortization of inventory fair value associated with acquisition of TRx and Avadel's pediatric products 0 22,603
Change in fair value of Investment in Aytu (7,079,821) 0
Change in fair value of warrant liability and unit purchase option liability (11,280) 47,577
Change in value of Guarantee (1,755,000) 0
Change in fair value of contingent consideration 0 180,402
Other 0 21,412
Changes in assets and liabilities:    
Accounts receivable, net (695,761) 439,159
Other receivables (1,962,812) (62,014)
Inventory, net 5,058 41,195
Prepaid expenses and other assets 22,676 281,051
Accounts payable 250,970 (196,671)
Income taxes payable (551,671) (217,608)
Accrued expenses and other liabilities (141,873) 2,074,278
Lease liability, net 157,143 0
Net cash used in operating activities (5,740,074) (3,121,552)
Investing activities    
Net cash paid in merger with Aevi (1,250,650) 0
Purchase of property and equipment 0 (165,969)
Net cash used in investing activities (1,250,650) (165,969)
Financing activities    
Proceeds from exercise of stock options and warrants 74,207 94,177
Proceeds from registered direct offering, net 5,136,184 0
Proceeds from sale of shares pursuant to common stock private placement, net 3,887,991 0
Proceeds from underwritten public offering, net 0 8,975,960
Payment of contingent consideration 0 (228,678)
Payment of long-term debt 0 (24,342)
Net cash provided by financing activities 9,098,382 8,817,117
Increase in cash, cash equivalents and restricted cash 2,107,658 5,529,596
Cash, cash equivalents, and restricted cash at beginning of period 3,728,918 10,746,756
Cash, cash equivalents, and restricted cash at end of period 5,836,576 16,276,352
Supplemental disclosures of cash flow information    
Cash paid for interest 0 262,500
Cash paid for taxes 316,000 378,025
Supplemental disclosures of non-cash activities    
Issuance of common stock in Aevi Merger 15,495,578 0
Leased asset obtained in exchange for new operating lease liability 0 743,025
Cash and cash equivalents 5,659,384 16,121,388
Restricted cash, current 64,643 77,846
Restricted cash, non-current $ 112,549 $ 77,118